KR20250013185A - 아자-테트라시클릭 옥사제핀 화합물 및 이의 용도 - Google Patents
아자-테트라시클릭 옥사제핀 화합물 및 이의 용도 Download PDFInfo
- Publication number
- KR20250013185A KR20250013185A KR1020247041569A KR20247041569A KR20250013185A KR 20250013185 A KR20250013185 A KR 20250013185A KR 1020247041569 A KR1020247041569 A KR 1020247041569A KR 20247041569 A KR20247041569 A KR 20247041569A KR 20250013185 A KR20250013185 A KR 20250013185A
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- substituted
- stereoisomer
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343959P | 2022-05-19 | 2022-05-19 | |
| US63/343,959 | 2022-05-19 | ||
| PCT/US2023/022914 WO2023225302A1 (en) | 2022-05-19 | 2023-05-19 | Aza-tetracyclic oxazepine compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250013185A true KR20250013185A (ko) | 2025-01-31 |
Family
ID=86895902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247041569A Pending KR20250013185A (ko) | 2022-05-19 | 2023-05-19 | 아자-테트라시클릭 옥사제핀 화합물 및 이의 용도 |
Country Status (17)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4716531A2 (en) * | 2023-05-22 | 2026-04-01 | Board of Regents, The University of Texas System | Heterocyclic compounds as nras inhibitors |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202540122A (zh) * | 2023-11-22 | 2025-10-16 | 美商建南德克公司 | Kras-g12d之氮雜-四環氧氮呯抑制劑的多晶型物及合成方法 |
| WO2025123007A1 (en) * | 2023-12-08 | 2025-06-12 | Kestrel Therapeutics Inc. | Ras inhibitors and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194134A1 (en) | 2024-03-15 | 2025-09-18 | Genentech, Inc. | Linearly substituted oxazepin-5-one kras-g12d inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026011344A1 (en) * | 2024-07-10 | 2026-01-15 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026039659A1 (en) * | 2024-08-14 | 2026-02-19 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as ras inhibitors |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026073024A1 (en) * | 2024-09-30 | 2026-04-02 | Gilead Sciences, Inc. | Kras g12d inhibitors for the treatment of cancer |
| WO2026080548A1 (en) | 2024-10-10 | 2026-04-16 | Genentech, Inc. | Method of treating cancer using the kras g12d inhibitor gcd-7035 |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121108144B (zh) * | 2025-09-02 | 2026-07-03 | 领泰生物医药(绍兴)有限公司 | 一种含氮杂多环化合物的制备方法及其中间体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CN116867792A (zh) | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2023018812A1 (en) | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| JP2024532735A (ja) | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| TW202315626A (zh) | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023030495A1 (en) | 2021-09-03 | 2023-03-09 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| CN118019746A (zh) | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| CN116199703A (zh) | 2021-12-01 | 2023-06-02 | 江苏恒瑞医药股份有限公司 | 稠合四环杂环化合物、其制备方法及其在医药上的应用 |
| WO2023103906A1 (zh) | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN116332948A (zh) | 2021-12-22 | 2023-06-27 | 翰森生物有限责任公司 | 一种含氮四环化合物及其制备方法和药用用途 |
| JP2025504041A (ja) | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2023265688A1 (en) | 2022-05-06 | 2024-10-17 | PAQ Therapeutics Inc. | Kras g12d proteolysis targeting chimeras |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| CN117462688A (zh) | 2022-07-28 | 2024-01-30 | 江苏恒瑞医药股份有限公司 | 一种包含kras g12d抑制剂的组合物 |
| KR20250037564A (ko) | 2022-07-29 | 2025-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Kras g12d 억제제를 포함하는 약학적 조성물 |
| WO2024032704A1 (en) | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| CN117771378A (zh) | 2022-09-29 | 2024-03-29 | 贝达药业股份有限公司 | 提高kras抑制剂生物利用度的药物组合及其应用 |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| TW202430182A (zh) * | 2022-12-14 | 2024-08-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物,及其製備和治療用途 |
| CN118221699A (zh) | 2022-12-20 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | 一种kras g12d抑制剂的可药用盐、晶型及其制备方法 |
| TW202430184A (zh) | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
-
2023
- 2023-05-19 CN CN202380041256.4A patent/CN119365467A/zh active Pending
- 2023-05-19 EP EP23732731.7A patent/EP4526309A1/en active Pending
- 2023-05-19 CA CA3257445A patent/CA3257445A1/en active Pending
- 2023-05-19 IL IL316696A patent/IL316696A/en unknown
- 2023-05-19 JP JP2024568561A patent/JP7735594B2/ja active Active
- 2023-05-19 KR KR1020247041569A patent/KR20250013185A/ko active Pending
- 2023-05-19 AU AU2023272945A patent/AU2023272945A1/en active Pending
- 2023-05-19 US US18/199,449 patent/US20240025919A1/en not_active Abandoned
- 2023-05-19 WO PCT/US2023/022914 patent/WO2023225302A1/en not_active Ceased
- 2023-05-19 PE PE2024002607A patent/PE20250752A1/es unknown
- 2023-05-19 AR ARP230101266A patent/AR129388A1/es unknown
- 2023-05-19 CR CR20240508A patent/CR20240508A/es unknown
- 2023-05-19 TW TW112118800A patent/TW202400170A/zh unknown
-
2024
- 2024-05-28 US US18/676,200 patent/US12338256B2/en active Active
- 2024-10-25 ZA ZA2024/08076A patent/ZA202408076B/en unknown
- 2024-11-14 CL CL2024003491A patent/CL2024003491A1/es unknown
- 2024-11-15 MX MX2024014176A patent/MX2024014176A/es unknown
- 2024-12-17 CO CONC2024/0017330A patent/CO2024017330A2/es unknown
-
2025
- 2025-04-25 US US19/190,368 patent/US20260062425A1/en active Pending
- 2025-08-26 JP JP2025140269A patent/JP2026000916A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR129388A1 (es) | 2024-08-21 |
| CA3257445A1 (en) | 2023-11-23 |
| ZA202408076B (en) | 2026-01-28 |
| WO2023225302A1 (en) | 2023-11-23 |
| US20240025919A1 (en) | 2024-01-25 |
| CN119365467A (zh) | 2025-01-24 |
| JP2026000916A (ja) | 2026-01-06 |
| PE20250752A1 (es) | 2025-03-13 |
| US20260062425A1 (en) | 2026-03-05 |
| US20240368186A1 (en) | 2024-11-07 |
| CL2024003491A1 (es) | 2025-04-11 |
| JP7735594B2 (ja) | 2025-09-08 |
| MX2024014176A (es) | 2024-12-06 |
| TW202400170A (zh) | 2024-01-01 |
| US12338256B2 (en) | 2025-06-24 |
| CO2024017330A2 (es) | 2024-12-30 |
| AU2023272945A1 (en) | 2024-11-07 |
| CR20240508A (es) | 2024-12-20 |
| EP4526309A1 (en) | 2025-03-26 |
| IL316696A (en) | 2024-12-01 |
| JP2025517395A (ja) | 2025-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12338256B2 (en) | Aza-tetracyclic oxazepine compounds and uses thereof | |
| TWI868441B (zh) | 非環氧氮呯化合物及其用途 | |
| JP7862413B2 (ja) | 四環系オキサゼピン化合物及びその使用 | |
| AU2024200904B2 (en) | Fused ring compounds | |
| JP2025535367A (ja) | 6-アザ部分を含むオキサゼピン化合物およびその使用 | |
| WO2025111582A1 (en) | Aza-tetracyclic oxazepine inhibitors of kras-g12d | |
| WO2025194134A1 (en) | Linearly substituted oxazepin-5-one kras-g12d inhibitors | |
| CN104125959A (zh) | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物 | |
| HK40099028A (en) | Oxazepine compounds and uses thereof in the treatment of cancer | |
| TW201706256A (zh) | 取代脲衍生物及其在藥物中的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |